Apoptosis News and Research RSS Feed - Apoptosis News and Research

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.
Scientists propose use of mathematical models to find better treatment for bladder cancer

Scientists propose use of mathematical models to find better treatment for bladder cancer

MIPT scientists together with their colleagues from St. Petersburg and Israel have analyzed more than 500 previously published scientific articles and proposed their own approach to the choice of methods used for the treatment of one of the most common cancers. [More]
Structural movie reveals step-by-step creation of chemical that plays important role in some cancers

Structural movie reveals step-by-step creation of chemical that plays important role in some cancers

An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers. [More]
Study reveals link between genomic instability, aneuploidy and cancer

Study reveals link between genomic instability, aneuploidy and cancer

A recent analysis of 43,205 human tumours unveiled that 68% of solid tumours are aneuploid, that is to say, they have an altered number of chromosomes. In recent years, scientists have attempted to clarify whether this aneuploidy contributes to tumour development or whether it is a co-lateral effect of the genomic instability of cancer cells, which increase the rate of mutations and the likelihood of cancer. [More]
UC San Diego School of Medicine launches new NAFLD Research Center

UC San Diego School of Medicine launches new NAFLD Research Center

Roughly one-quarter of all Americans - an estimated 100 million adults and children - have nonalcoholic fatty liver disease (NAFLD), a chronic condition that can lead to cirrhosis, liver cancer and liver failure. [More]
Duke researchers identify promising target for renal cell carcinomas

Duke researchers identify promising target for renal cell carcinomas

All cells need nutrients, but cancer cells are notoriously power hungry. As a result, cancer cells must alter their metabolism to provide the additional fuel needed for them to survive, grow and spread. [More]
ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar. [More]
HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA Bioscience International President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. [More]
MGH study may lead to first nonsurgical treatment for seborrheic keratoses

MGH study may lead to first nonsurgical treatment for seborrheic keratoses

An investigation into the molecular mechanisms responsible for the most common type of benign skin lesion may lead to the first nonsurgical treatment for the growths called seborrheic keratoses (SKs), which in addition to being cosmetically unattractive are often worrisome to patients. [More]
Using centrifugal elutriation and flow cytometry to answer biological questions: an interview with Peter Lopez

Using centrifugal elutriation and flow cytometry to answer biological questions: an interview with Peter Lopez

Flow Cytometry, the measurement of various cellular characteristics as they flow through a measuring apparatus, has so many applications that it's hard to know where to begin. [More]
Using acidity to detect cancer

Using acidity to detect cancer

Normally, tissues demonstrate a slightly acidic intracellular pH (pHi) and slightly alkaline extracellular pH (pHe). However, proliferating tissues demonstrate transient pH Gradient Reversal i.e. alkalinization of pHi and acidification of pHe. [More]
Immune killer cells use microptosis pathway to kill intracellular parasites

Immune killer cells use microptosis pathway to kill intracellular parasites

The immune system's killer cells deliver a tightly controlled, 3-phase knockout punch that kills intracellular parasites through a novel pathway that an international team led by researchers from the Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital have named "microptosis." [More]
Cornell researchers identify potent cancer-killing proteins that can kill tumors in bloodstream

Cornell researchers identify potent cancer-killing proteins that can kill tumors in bloodstream

Cornell researchers have discovered potent cancer-killing proteins that can travel by white blood cells to kill tumors in the bloodstream of mice with metastatic prostate cancer. The breakthrough study will be published Feb. 10 as the cover article in the Journal of Controlled Release. [More]
E-cigarettes damage cells in ways that could lead to cancer

E-cigarettes damage cells in ways that could lead to cancer

Adding to growing evidence on the possible health risks of electronic cigarettes, a lab team at the Veterans Affairs San Diego Healthcare System tested two products and found they damaged cells in ways that could lead to cancer. The damage occurred even with nicotine-free versions of the products. [More]
Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. [More]
HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL). [More]
UB study traces how enigmatic molecules help cancer self-destruct

UB study traces how enigmatic molecules help cancer self-destruct

You've probably never heard of "sphingolipids" before. But these curiously named organic compounds play a vital role in one of humanity's most well-known diseases: cancer. [More]
Mitochondrial variation and viable pregnancy: an interview with Dr Elpida Fragouli

Mitochondrial variation and viable pregnancy: an interview with Dr Elpida Fragouli

Embryos require adequate amounts of energy so that they can successfully progress through each of their cell divisions. [More]
New CRC aims to better understand autophagy at molecular and cellular level

New CRC aims to better understand autophagy at molecular and cellular level

The German Research Foundation (Deutsche Forschungsgemeinschaft/DFG) has approved 11 M € for the next four years for establishing a CRC on selective autophagy under the lead of Goethe University. Autophagy literally means "self-eating" and refers to a sophisticated system in which cellular waste is specifically detected and removed. [More]
OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma. [More]
MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Researchers at the UC Davis Comprehensive Cancer Center have shown that the microRNA, miR-124, reduced tumor growth and increased cell death in castration-resistant prostate cancer. [More]
Advertisement
Advertisement